U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07391644) titled 'A Study of JSKN027 in Patients With Advanced Solid Tumors' on Jan. 30.
Brief Summary: This is a first-in-human, open-label, multicenter Phase 1 (Ia/Ib) clinical study conducted in China to evaluate the safety and tolerability of JSKN027 in patients with advanced malignant solid tumors. The study will also assess the pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of JSKN027, and determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D).
The study includes two parts. Part Ia is a dose-escalation phase designed to evaluate the safety and tolerability of increasing dose level...